Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.

Do institutionals and insiders believe in RXRX or VCEL?

63.6% of Recursion Pharmaceuticals shares are held by institutional investors. 22.3% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is RXRX or VCEL more profitable?

Vericel has a net margin of -10.11% compared to Recursion Pharmaceuticals' net margin of -533.45%. Vericel's return on equity of -9.26% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-533.45%	-57.15%	-38.10%
Vericel	-10.11%	-9.26%	-6.64%

Does the MarketBeat Community believe in RXRX or VCEL?

Vericel received 314 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 62.81% of users gave Vericel an outperform vote while only 41.38% of users gave Recursion Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Recursion Pharmaceuticals	Outperform Votes 12 41.38%	Underperform Votes 17 58.62%
Vericel	Outperform Votes 326 62.81%	Underperform Votes 193 37.19%

Which has more volatility and risk, RXRX or VCEL?

Recursion Pharmaceuticals has a beta of -0.43, meaning that its stock price is 143% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.

Does the media favor RXRX or VCEL?

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Vericel. MarketBeat recorded 6 mentions for Recursion Pharmaceuticals and 3 mentions for Vericel. Vericel's average media sentiment score of 1.30 beat Recursion Pharmaceuticals' score of 1.05 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, RXRX or VCEL?

Vericel has higher revenue and earnings than Recursion Pharmaceuticals. Vericel is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$39.84 million	43.12	-$239.48 million	-$1.38	-6.47
Vericel	$163.70 million	9.75	-$16.71 million	-$0.37	-90.67

Do analysts rate RXRX or VCEL?

Recursion Pharmaceuticals currently has a consensus target price of $12.40, suggesting a potential upside of 38.86%. Vericel has a consensus target price of $37.25, suggesting a potential upside of 11.03%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Vericel	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Vericel beats Recursion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.